Project Grant R01AR083462

Award Date 7/5/24
Completion Date 6/30/29
Dollars Obligated $1.6M
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This Project Grant award of $623,628 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support the University of Vermont & State Agricultural College's research to investigate how human long non-coding RNAs (lncRNAs) epigenetically regulate human mesenchymal stem cell commitment and osteoblast lineage progression. The research aims to mechanistically define the...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $605,253 to The Trustees of the University of Pennsylvania to investigate the mechanical crosstalk between the intervertebral disc and adjacent facet joints during spinal degeneration and repair. The research aims to characterize the progression of facet osteoarthritis following disc...
This Project Grant award, ID R21AR084126, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The $783,176 award supports research to develop and validate a quantitative spine imaging methodology using photon-counting detector CT (PCD-CT) technology to comprehensively characterize bone quality, including cortical and trabecular microstructures, in patients with...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $279,354 to Northwestern University to conduct research on preventing bone loss and maintaining bone mass after spinal cord injury. The study will evaluate the use of the drug denosumab followed by zoledronic acid to prevent significant bone loss that commonly occurs in individuals with...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is focused on engineering the fetal environment to enable in-utero treatment of spina bifida bone defects. The $600,475 award to the University of California, Davis will support the development of a collagen-based scaffold modified with specific integrin ligands and placental mesenchymal...
This Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences (CFDA 47.049) program provides $150,001 to study the individual and collective behavior of osteoclast cells, which play a critical role in bone resorption and remodeling. The project, led by a physician specializing in orthopedic clinical research and a physicist focusing on collective organism dynamics, aims to observe the movement and bone degradation patterns of individual and groups of...
This Project Grant award of $3,069,994.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research Federal Grant Program (CFDA 93.121), supports a multi-faceted research program focused on elucidating the role of skeletal stem cell plasticity in craniofacial bone diseases. The primary awardee, the University of Texas Health Science Center at Houston, will investigate the fates and functions of periosteal and endosteal stem cells in...
This Project Grant award, provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to resolve the mechanism of osteoclast multinucleation and signaling in bone remodeling. The $249,000 award to the Rector & Visitors of the University of Virginia will fund a 3-year research project to: 1) identify the domain of the lupus La protein that regulates osteoclast...
This Project Grant award of $2,549,716.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research by New York University School of Medicine to investigate the role of inflammation in the decline of skeletal stem and progenitor cell function during aging. The goal is to identify therapeutic targets to improve bone health and fracture repair in elderly patients. Key focus areas include: Defining the molecular mechanisms regulating the inflammatory response in skeletal...
This $225,306 Project Grant award from the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) supports a collaborative research project between researchers at the University of Southern California (USC) and a German partner to investigate the long-term impact of early-life growth signals on adult hematopoietic (blood) stem cell function and selection. The key products and services to be delivered under this 3-year award include: 1) using stem cell transplantation and...

DISCOVERY OF A STEM CELL GOVERNING VERTEBRAL PHYSIOLOGY - PROJECT SUMMARY VERTEBRAE AND LONG BONES DISPLAY MARKED DIFFERENCES ACROSS A RANGE OF CLINICAL AND BASIC PROPERTIES, SUCH AS THEIR BASIC ARCHITECTURE, RESPONSIVENESS TO PTH, THEIR RATE OF SEEDING WITH SOLID TUMOR METASTASES, OR THE TYPES OF DEVELOPMENTAL AND DEGENERATIVE DISEASES PRESENT. THE ETIOLOGY OF THESE DIFFERENCES HAS REMAINED ELUSIVE, IN PART DUE TO THE CURRENT STATE OF SKELETAL STEM CELL (SSC) BIOLOGY THAT LARGELY CONSIDERS SKELETAL STEM CELLS IN A MONOLITHIC MANNER, WITHOUT DRAWING CLEAR DISTINCTIONS IN CELL TYPE BASED ON BONE OF ORIGIN. HERE, WE HAVE IDENTIFIED A VERTEBRAL SKELETAL STEM CELL (VSSC), HAVING ESTABLISHED THAT IT DISPLAYS A COMPREHENSIVE SET OF STEMNESS FEATURES, INCLUDING THE ABILITY TO SELF-RENEW ACROSS MULTIPLE ROUNDS OF TRANSPLANTATION, THE ABILITY TO SERIALLY FORM BONE ORGANOIDS ACROSS MULTIPLE ROUNDS OF TRANSPLANTATION AND REISOLATION, LONG-TERM LABEL RETENTION AFTER A PULSE WITH A CHROMATIN BOUND H2B-GFP MARKER, IN VIVO MULTIPOTENCY THROUGH AN ABILITY TO GIVE RISE TO CHONDROCYTES, OSTEOBLASTS AND ADIPOCYTE IN VIVO, AND BEING LONG-LIVED IN VIVO. THIS VSSC TYPE IS SPECIFIC FOR VERTEBRAE, BEING COMPLETELY ABSENT FROM LONG BONES. THESE VSSCS HAVE A CLEAR PHYSIOLOGIC CONTRIBUTION TO VERTEBRAL MINERALIZATION, AS DELETING GENES REQUIRED FOR OSTEOBLAST DIFFERENTIATION WITH A ZIC1- CRE CREATED FOR THIS PROJECT TARGETING THE LINEAGE OF THIS VSSC PRODUCED MARKED DEFECTS IN THE MINERALIZATION OF BOTH THE DORSAL NEURAL ARCH AND THE VERTEBRAL BODY AND NO DETECTABLE PHENOTYPE IN LONG BONES. THUS, WE HAVE HERE IDENTIFIED A VSSC, INCLUDING GENERATING 2 CRE LINES TARGETING THIS CELL, THAT MEETS ALL PUBLISHED CRITERIA TO BE DEFINED AS A NOVEL SSC TYPE. HERE, WE PROPOSE TO ADDRESS A SERIES OF KEY ISSUES ENABLED BY THIS DISCOVERY TO FURTHER DEVELOP THE CLINICAL AND PHYSIOLOGIC ROLE OF THIS NEW STEM CELL TYPE. FIRST, (AIM 1) WE WILL DETERMINE THE UNIQUE CELLULAR FEATURES OF THE VERTEBRAL BONE VERSUS LONG BONES, DEMONSTRATE WHICH OF THESE FEATURES ARE DUE TO ZIC1+VSSCS, THE RELATIONSHIP OF ZIC1+VSSCS TO OTHER SKELETAL PROGENITOR CELL TYPES IDENTIFIED IN THE LITERATURE AND THE FUNCTION OF VSSC-SPECIFIC TRANSCRIPTION FACTORS AND SECRETED LIGANDS. NEXT (AIM 2), WE WILL ESTABLISH THAT THIS VSSC IS A KEY CELL MEDIATING SPINE FUSION, A COMMON ORTHOPEDIC MANAGEMENT STRATEGY TO TREAT A VARIETY OF SPINE DEGENERATIVE DISORDERS. LASTLY (AIM 3), WE WILL BUILD UPON PRELIMINARY EFFORTS IDENTIFYING A HUMAN COUNTERPART OF THE MURINE VSSC TO FULLY ESTABLISH THE IDENTITY AND DIFFERENTIATION HIERARCHY OF THE HUMAN VSSC AND TO DETERMINE THE FUNCTIONAL CONSERVATION OF VSSC-LINEAGE DEFINING TRANSCRIPTION FACTORS. ALTOGETHER, THIS PROJECT WILL ESTABLISH THE EXISTENCE AND UNIQUE PROPERTIES OF A NEW AND DISTINCT VSSC CELL TYPE IN HUMANS AND MICE AND FACILITATE SUBSEQUENT STUDIES INTO HOW THIS VSSC MEDIATES VERTEBRAL SKELETAL DISORDERS OR HOW THESE DISORDERS CAN BE THERAPEUTICALLY ADDRESSED BY TARGETING THIS NEW STEM CELL.

Posted 7/5/24, 12:00 AM